Lexaria Bioscience prices public offering of 2.1M units at $0.95/unit for $2.0M gross proceeds

Lexaria Bioscience Corp.

2,106,000 units priced at $0.95 each, each unit comprising one share of common stock and one warrant.
Gross proceeds expected ~$2.0M before fees; warrants exercisable at $0.95 for 5 years.
Offering expected to close May 11, 2023; Maxim Group LLC sole placement agent.
Registration statement on Form S-1 (File No. 333-271096) declared effective May 8, 2023.

item 1.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Lexaria Bioscience Corp. entered into Placement Agency Agreement with Maxim Group LLC (effective 2023-05-08).

Action: entry
Agreement: underwriting
Counterparty: Maxim Group LLC
Effective: 2023-05-08

Exact text from the filing

On May 8, 2023, Lexaria Bioscience Corp. (the “Company”) entered into a placement agency agreement dated as of May 8, 2023 (the “PAA”) with Maxim Group LLC (the “Placement Agent”)

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Lexaria Bioscience Corp. entered into Security Purchase Agreement with certain institutional investors valued at up to an aggregate of $247,000 of Units (effective 2023-05-08).

Action: entry
Agreement: equity purchase
Counterparty: certain institutional investors
Value: up to an aggregate of $247,000 of Units
Effective: 2023-05-08

Exact text from the filing

On May 8, 2023, the Company also entered into a security purchase agreement (the “Purchase Agreement”) with certain institutional investors named therein (the “Purchasers”) in connection with the Offering.

View on SEC.gov

25 material agreements filed in the last 30 days. Browse all material agreements →

Lexaria Bioscience Corp. filing history →

Source: SEC EDGAR

accession 0001640334-23-000800

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.